AB89828

Anti-PD1 antibody

Name: Anti-PD1 antibody (ab89828) | Abcam
Brand: Abcam Limited
SKU: AB89828

Be the first to review this product! Submit a review

(6 Publications)

Mouse Polyclonal PD1 antibody. Carrier free. Suitable for WB and reacts with Human samples. Cited in 6 publications. Immunogen corresponding to Recombinant Full Length Protein corresponding to Human PDCD1.

View Alternative Names

CD279, PD1, PDCD1, Programmed cell death protein 1, Protein PD-1, hPD-1

3 Images

Unknown

Western blot - Anti-PD1 antibody (AB89828)

All lanes:

Western blot - Anti-PD1 antibody (ab89828) at 1 µg/mL

All lanes:

HeLa cell lysate at 50 µg

Predicted band size: 32 kDa

Observed band size: ~32 kDa

true

Unknown

Western blot - Anti-PD1 antibody (AB89828)

All lanes:

Western blot - Anti-PD1 antibody (ab89828) at 1 µg/mL

Lane 1:

PD1 transfected 293T cell lysate at 25 µg

Lane 2:

non transfected 293T cell lysate at 25 µg

Predicted band size: 32 kDa

Observed band size: 32 kDa,~38 kDa,~45 kDa

true

Unknown

Western blot - Anti-PD1 antibody (AB89828)

All lanes:

Western blot - Anti-PD1 antibody (ab89828) at 1 µg/mL

All lanes:

human stomach tissue lysate at 50 µg

Predicted band size: 32 kDa

Observed band size: 37 kDa

true

Key facts

Host species

Mouse

Clonality

Polyclonal

Isotype

IgG

Carrier free

Yes

Reacts with

Human

Applications

applications

Immunogen

Recombinant Full Length Protein corresponding to Human PDCD1.

Q15116

style

left-column

Reactivity data

{ "title": "Reactivity Data", "filters": { "stats": ["", "Species", "Dilution Info", "Notes"], "tabs": { "all-applications": {"fullname" : "All Applications", "shortname": "All Applications"}, "WB" : {"fullname" : "Western blot", "shortname":"WB"} }, "product-promise": { "all": "all", "testedAndGuaranteed": "tested", "guaranteed": "expected", "predicted": "predicted", "notRecommended": "not-recommended" } }, "values": { "Human": { "WB-species-checked": "testedAndGuaranteed", "WB-species-dilution-info": "1 µg/mL", "WB-species-notes": "<p></p>" } } }

style

left-column

style

left-column

Properties and storage information

Form

Liquid

Purification technique

Affinity purification Protein A

Storage buffer

pH: 7.4 Constituents: PBS

Shipped at conditions

Blue Ice

Appropriate short-term storage conditions

+4°C

Appropriate long-term storage conditions

-20°C

Aliquoting information

Upon delivery aliquot

Storage information

Avoid freeze / thaw cycle

style

left-column

Supplementary information

This supplementary information is collated from multiple sources and compiled automatically.

PD1 also known as Programmed Cell Death Protein 1 or PDCD1 is a transmembrane protein that plays a critical role in regulating immune responses. It has a mass of approximately 55 kDa. PD1 is expressed on the surface of T cells B cells and some myeloid cells. PD1’s expression increases upon activation of these immune cells assisting in maintaining peripheral tolerance. Researchers often use PD1 mouse models and chimeric antibodies to explore the function of PD1 for experimental purposes. Antibodies such as anti-PD1 such as EH12.2H7 help in blocking PD1 interaction to study its role further.

Biological function summary

PD1 serves as an inhibitory receptor acting as a checkpoint in the immune system. It becomes part of an immune-suppressive complex when it binds with its ligands PD-L1 or PD-L2 which are expressed on various cell types including some tumor cells. This interaction suppresses the proliferation of T cells and cytokine production contributing to immune homeostasis. By controlling T cell activity PD1 limits autoimmunity but can also reduce the immune system's capability to attack cancer cells.

Pathways

PD1 functions in the immune checkpoint pathway a critical regulatory circuit in immune regulation. The engagement of PD1 with its ligands initiates a cascade that inhibits the function and proliferation of T cells through downstream SHP-2 phosphatase activity. This pathway frequently involves other regulatory proteins like CTLA-4 and is an important mechanism by which the body modulates immune responses. Related pathways often intersect with those involving T cell receptor signaling and contribute to the overall modulation of immune activity.

PD1 has a significant role in cancer and autoimmune disorders. PD1 expression can allow tumors to evade immune surveillance making PD1 a target for cancer therapies such as anti-PD1 antibodies which aim to block PD1 and restore T cell activity. The interaction of PD1 with cancer-related proteins like PD-L1 facilitates tumor immune evasion. In autoimmune disorders PD1’s regulation of immune balance can become dysregulated leading to persistent immune activation and tissue damage. Understanding PD1 and its interaction with proteins such as PD-L1 helps in developing therapeutic strategies for both cancer and autoimmune conditions.

style

left-column

style

left-column

Product protocols

For this product, it's our understanding that no specific protocols are required. You can visit:

Visit the General protocols
Visit the Troubleshooting

style

left-column

Target data

The protein expressed by the gene PDCD1 functions as an inhibitory receptor on antigen-activated T-cells, playing a critical role in the induction and maintenance of immune tolerance to self. It delivers inhibitory signals by binding to the ligands CD274/PDCD1L1 and CD273/PDCD1LG2. Tumors exploit the PDCD1-mediated inhibitory pathway to attenuate anti-tumor immunity, enabling tumor survival by evading immune system destruction. The interaction with CD274/PDCD1L1 inhibits the effector function of cytotoxic T lymphocytes (CTLs). Blocking the PDCD1-mediated pathway can reverse the exhausted T-cell phenotype and normalize the anti-tumor response, providing a rationale for cancer immunotherapy. This supplementary information is collated from multiple sources and compiled automatically.

See full target information PDCD1

style

left-column

Publications (6)

Recent publications for all applications. Explore the full list and refine your search

Life (Basel, Switzerland) 14: PubMed38672781

2024

Approaches to Characterize and Quantify Extracellular Vesicle Surface Conjugation Efficiency.

Applications

Unspecified application

Species

Unspecified reactive species

Leora Goldbloom-Helzner,Harjn Bains,Aijun Wang

Cancers 14: PubMed35681615

2022

Fusogenic Hybrid Extracellular Vesicles with PD-1 Membrane Proteins for the Cytosolic Delivery of Cargos.

Applications

Unspecified application

Species

Unspecified reactive species

Raga Ishikawa,Shosuke Yoshida,Shin-Ichi Sawada,Yoshihiro Sasaki,Kazunari Akiyoshi

Frontiers in oncology 11:622263 PubMed33816255

2021

Overexpressed Tumor Suppressor Exosomal miR-15a-5p in Cancer Cells Inhibits PD1 Expression in CD8+T Cells and Suppresses the Hepatocellular Carcinoma Progression.

Applications

Unspecified application

Species

Unspecified reactive species

Hong-Yu Zhang,Hong-Xia Liang,Shu-Huan Wu,He-Qing Jiang,Qin Wang,Zu-Jiang Yu

BMC systems biology 13:30 PubMed30894166

2019

How to schedule VEGF and PD-1 inhibitors in combination cancer therapy?

Applications

Unspecified application

Species

Unspecified reactive species

Xiulan Lai,Avner Friedman

BMC systems biology 11:70 PubMed28724377

2017

Combination therapy for melanoma with BRAF/MEK inhibitor and immune checkpoint inhibitor: a mathematical model.

Applications

Unspecified application

Species

Unspecified reactive species

Xiulan Lai,Avner Friedman

PloS one 12:e0178479 PubMed28542574

2017

Combination therapy of cancer with cancer vaccine and immune checkpoint inhibitors: A mathematical model.

Applications

Unspecified application

Species

Unspecified reactive species

Xiulan Lai,Avner Friedman

View all publications

style

left-column

style

left-column

style

right-column